TY  - JOUR
AU  - Escolar-Albaladejo, Ginés
AU  - Barón-Esquivias, Gonzalo
AU  - Zamorano, José Luis
AU  - Betegón-Nicolás, Lourdes
AU  - Canal-Fontcuberta, Cristina
AU  - de Salas-Cansado, Marina
AU  - Rubio-Rodríguez, Darío
AU  - Rubio-Terrés, Carlos
PY  - 2016
DO  - 10.1016/j.aprim.2015.04.012
UR  - http://hdl.handle.net/10668/9797
T2  - Atencion primaria
AB  - To assess the cost-effectiveness of apixaban versus acetylsalicylic acid (ASA) in stroke prevention in patients with non-valvular atrial fibrillation (NVAF) with contraindications of vitamin K antagonists in Spain. A Markov model was adapted,...
LA  - es
KW  - Acetylsalicylic acid
KW  - Apixaban
KW  - Apixabán
KW  - Cost-effectiveness
KW  - Coste-utilidad
KW  - Fibrilación auricular no valvular
KW  - Non-valvular atrial fibrillation
KW  - Ácido acetilsalicílico
KW  - Aged
KW  - Aspirin
KW  - Atrial Fibrillation
KW  - Cost-Benefit Analysis
KW  - Female
KW  - Humans
KW  - Male
KW  - Markov Chains
KW  - Pyrazoles
KW  - Pyridones
KW  - Spain
KW  - Stroke
TI  - [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain].
T2  - Análisis coste-utilidad de apixabán frente al ácido acetilsalicílico en la prevención del ictus en pacientes con fibrilación auricular no valvular en España.
TY  - research article
VL  - 48
ER  -